CD44 and ovarian carcinoma: Follow-up of 92 ovarian cancer patients in the present study revealed that the mortality rate of chemotherapy-resistant patients was significantly higher than that of chemotherapy-sensitive patients, However, as a greater percentage of deaths in the chemotherapy resistant group were from stage III cancers, we cannot conclusively state that glycosylated Lewis y antigen and CD44 are associated with survival outcomes.